NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: INDOCO · data 2026-10-31
Indoco Remedies Limited
In plain words
Price: 27.7% below its 52-week high of ₹288.
Delivery: 45.0% of traded shares were kept for delivery over the last 10 sessions, against 39.5% over the last 60.
Latest results: a net profit of ₹18 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,909 cr |
| Net profit (last 12 months) | ₹32 cr |
| Sales growth, 3 years (yearly) | 3.0% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 58.9% (unchanged in a year), pledged 0.0%, institutions 18.3%.
P/E 60.1, P/B 1.9, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE -9.7%, ROCE -2.0%, operating margin 1.8%: how much profit it earns on the money it uses.
Debt/equity 1.15, Profit growth — and sales growth 3.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-9.7%).
- Thin operating margin (1.8%).
- Slow sales growth (3.0% a year over 3 years).
- Expensive on earnings (P/E 60.1).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
Q2 FY27
Revenue: 520.17
Net Profit: 18.38
Operating Margin: 8.9
EPS: 2.11 turned to profit
Q2 FY27
राजस्व: 520.17
नेट लाभ: 18.38
परिचालन मार्जिन: 8.9
EPS: 2.11 मुनाफे में बदल गया
Q2 FY27
મહેસૂલ: ૫૨૦.૧૭
નેટ લાભ: ૧૮.૩૮
કાર્યકારી માર્જિન: ૮.૯
EPS: ૨.૧૧ મુનાફામાં બદલાયું
Written by AI from the filed numbers and checked against them. Not a recommendation.
Earnings call in brief (29 Oct 2026)
- No business update mentioned
- No orders and pipeline discussed
- No margins and costs talked about
- No capex mentioned
- No guidance stated
- No risks management mentioned
- कोई व्यवसाय अद्यतन उल्लेख नहीं किया गया
- कोई आदेश और पाइपलाइन पर चर्चा नहीं की गई
- कोई मार्जिन और लागत पर बात नहीं की गई
- कोई पूंजी व्यय उल्लेख नहीं किया गया
- कोई मार्गदर्शन उल्लेख नहीं किया गया
- कोई जोखिम प्रबंधन उल्लेख नहीं किया गया
- કોઈ બિઝનેસ અપડેટ ઉલ્લેખ નથી કરવામાં આવ્યો
- કોઈ ઓર્ડર અને પાઇપલાઈન પર ચર્ચા નથી કરવામાં આવી
- કોઈ માર્જિન અને ખર્ચ પર વાત નથી કરવામાં આવી
- કોઈ પૂંજી ખર્ચ ઉલ્લેખ નથી કરવામાં આવ્યો
- કોઈ માર્ગદર્શન ઉલ્લેખ નથી કરવામાં આવ્યો
- કોઈ જોખમ વ્યવસ્થાપન ઉલ્લેખ નથી કરવામાં આવ્યો
What management said on the call, summarised by AI from the official transcript and checked against it. Read the transcript. Not a recommendation.
Smart-money activity
30/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 28.5% over the last 20 sessions vs 9.3% in the 40 before (3.06x); shares delivered per day 0.68x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 12/15: 0 insider buy days (promoter group among them) and 3 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 3/15: 1 scheme hold it, about ₹44 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Insider ● Dividend
- 27 Oct 26Results Q2 FY27 results: turned to profit vs a year ago -2.6% next session
- 24 Sept 26Insider SAST disclosure: Aruna Suresh Kare +3 acquired 38,930 shares +1.3% next session
- 21 Sept 26Insider SAST disclosure: Ms. Aditi M Panandikar +1 acquired 4,000 shares +2.2% next session
- 10 Sept 26Dividend Dividend ₹0.2 (ex-date) +13.8% next session
- 3 Sept 26Insider SAST disclosure: Ms. Madhura Suresh Kare +1 acquired 10,000 shares -4.1% next session
- 28 Jul 26Results Q1 FY27 results: turned to profit vs a year ago -9.3% next session
- 7 May 26Results Q4 FY26 results: loss narrowed vs a year ago -0.3% next session
- 3 Feb 26Results Q3 FY26 results: loss widened vs a year ago +6.4% next session
- 6 Nov 25Results Q2 FY26 results: loss narrowed vs a year ago -3.7% next session
- 4 Sept 25Dividend Dividend ₹0.2 (ex-date) -2.9% next session
- 24 Jul 25Results Q1 FY26 results: turned to loss vs a year ago +1.9% next session
- 22 May 25Results Q4 FY25 results: turned to loss vs a year ago -6.9% next session
- 21 Jan 25Results Q3 FY25 results: turned to loss vs a year ago -13.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹520 cr | ₹18 cr | — | 8.9% | 2.11 |
| Jun 2026 | ₹468 cr | ₹65 cr | — | 8.8% | 7.09 |
| Mar 2026 | ₹476 cr | ₹-22 cr | — | 10.5% | -2.57 |
| Dec 2025 | ₹445 cr | ₹-30 cr | — | 7.1% | -3.2 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 58.92% | 58.86% | 58.86% | 58.90% |
| Foreign institutions (FII) | 1.64% | 1.27% | 0.94% | 1.10% |
| Domestic institutions (DII) | 16.64% | 17.68% | 18.15% | 18.15% |
| Mutual funds | 16.44% | 17.16% | 17.54% | 17.55% |
| Retail investors | 12.05% | 11.66% | 11.52% | 11.11% |
| Number of shareholders | 34,098 | 32,457 | 32,276 | 32,659 |
Common questions
What was Indoco Remedies Limited's latest quarterly profit?
Indoco Remedies Limited reported a net profit of ₹18 cr for the quarter ended Sept 2026, on revenue of ₹520 cr.
How much do promoters hold in Indoco Remedies Limited?
Promoters held 58.92% of Indoco Remedies Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Indoco Remedies Limited debt-free?
Its latest reported debt-to-equity ratio is 1.15, meaning borrowings are larger than shareholders' equity.
What is Indoco Remedies Limited's P/E ratio?
About 60.1, based on the last 12 months' earnings and a price of ₹208.3 (data 2026-10-31).
What is the 52-week high and low of Indoco Remedies Limited?
The 52-week high is ₹288 and the 52-week low is ₹162.19.
Mutual funds holding Indoco Remedies Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹44 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 0.48% | ₹44 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
| Syncom Formulation (India) Ltd. | ₹19.24 | ₹1,810 cr | 21.2 | — | 20.2% | 16.3% | 0 | +16.0% |
Compare INDOCO with BETA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INDOCO in NSE Scanner →